The Viread lawsuit is a mass-tort action in which roughly 24,000 plaintiffs accuse Gilead Sciences of deliberately delaying a safer HIV medication so it could keep selling Viread and its related tenofovir disoproxil fumarate (TDF) drugs at full patent value. The plaintiffs say that decision left them with kidney and bone injuries that a safer alternative would have prevented. The litigation’s future now depends on a pending California Supreme Court decision on whether a drugmaker can be sued for sitting on a better product rather than for selling a defective one.1Drug and Device Law Blog. The Duty To Innovate Arrives at the California Supreme Court
The Injuries Plaintiffs Blame on Viread
Viread, approved by the FDA in 2001, was the first TDF-based HIV treatment and became the backbone of Gilead’s HIV franchise.2Trustwell Law. Tenofovir TDF Long-term TDF use has been linked to chronic kidney disease, acute renal failure, Fanconi syndrome (a dysfunction of the kidney’s filtering tubes), and end-stage renal disease requiring dialysis.3National Library of Medicine. Tenofovir-Related Renal and Bone Toxicity On the skeletal side, patients have reported decreased bone mineral density, osteoporosis, osteomalacia, fractures, and tooth loss.4Lieff Cabraser. Gilead HIV Drugs
Viread’s FDA-approved label warned of kidney and bone risks from the outset, and acknowledged that clinical-study patients on Viread lost significantly more bone density than those on alternative treatments.5FDA. Viread Prescribing Information Plaintiffs say those warnings were not the real issue. Their claim is not that the label was inadequate or that TDF was defectively designed. It is that a safer drug existed and was withheld.
The Central Allegation: A Safer Drug Held Back
Plaintiffs allege Gilead developed tenofovir alafenamide (TAF), a compound with the same effectiveness as TDF but reduced kidney and bone toxicity, and then deliberately paused it to preserve TDF’s patent revenues.
Early clinical trials by 2002 suggested TAF was comparably effective to TDF with fewer risks.6FDLI. Gilead Tenofovir Cases In 2004, Gilead halted TAF development. The company says it did so because a two-week study of 20 patients showed no meaningful safety advantage.7Gilead Sciences. TDF Litigation Plaintiffs point instead to internal Gilead documents from 2003 that they describe as laying out a strategy to hold TAF back until TDF patents were closer to expiring.8STAT News. Gilead Suit Patent Hopping HIV Treatment
Gilead did not restart TAF research until around 2010. A Phase III trial in 2013 confirmed TAF’s reduced impact on bone and kidney function, and the FDA approved the first TAF-based drug, Genvoya, in 2015, more than a decade after Gilead paused the program.6FDLI. Gilead Tenofovir Cases2Trustwell Law. Tenofovir TDF TDF patents began expiring in 2017 and 2018.
One piece of evidence has drawn particular attention: a study Gilead itself commissioned that modeled the health consequences of patients staying on TDF instead of switching to safer alternatives. According to STAT News, the analysis projected an additional 16,000 excess deaths and 150,000 excess kidney and bone injuries over a nine-year period.8STAT News. Gilead Suit Patent Hopping HIV Treatment
Where the Cases Stand Now
The litigation runs on several tracks.
In California state court, about 24,000 individual lawsuits are consolidated under JCCP No. 5043 before Judge Andrew Y.S. Cheng in San Francisco Superior Court.9vLex. Gilead Life Sciences Inc Fourteen bellwether cases have been picked to go to trial first, and Gilead has said it will not discuss any broader settlement of the state claims until the first bellwether concludes.4Lieff Cabraser. Gilead HIV Drugs
A federal track proceeded separately in the Northern District of California before Judge Jon S. Tigar.10Drugwatch. Tenofovir Disoproxil Fumarate Lawsuits In June 2024, Gilead reached an agreement in principle to pay up to $40 million to resolve approximately 2,625 federal claims.11Gilead Sciences. Gilead Statement on Agreement in Principle To Resolve Federal TDF Litigation That works out to roughly $12,500 per claimant after fees and covers primarily lower-severity injuries; cases involving permanent disability or kidney failure are expected to be valued significantly higher.12AboutLawsuits.com. HIV Drug Gilead said the agreement was not an admission of liability.
Outside the United States, a Canadian class action was filed in April 2021 on behalf of Canadians prescribed TDF-based drugs. In March 2024, the British Columbia Supreme Court certified I.F. v. Gilead Sciences, Inc. as a national class proceeding. Gilead has appealed the certification.13Klein Lawyers. TDF Drug Injury
The California Supreme Court Question That Will Decide the Case
The most important development for anyone tracking the Viread lawsuit is not happening in a trial court. It is at the California Supreme Court, which is deciding whether the legal theory behind the entire mass tort is valid.
In 2024, the California Court of Appeal ruled in Gilead Tenofovir Cases, 98 Cal.App.5th 911, that plaintiffs’ negligence claims could go forward. The appellate court held that a drug manufacturer owes a duty of reasonable care to users of a drug it is selling when it knows of “a safer, and at least equally effective, alternative.”1Drug and Device Law Blog. The Duty To Innovate Arrives at the California Supreme Court The court grounded that duty in California’s general duty-of-care statute, Civil Code Section 1714, and said plaintiffs did not have to prove TDF itself was defective.14Morrison Foerster. Cases To Watch Gilead Life Sciences v Superior Court
Gilead petitioned for review, and the California Supreme Court granted it in May 2024. Industry interest has been heavy: 67 signatories filed 12 amicus briefs supporting Gilead by late 2024.7Gilead Sciences. TDF Litigation
Gilead’s core argument is that no jurisdiction has ever imposed liability for injuries caused by a non-defective product, and that when it paused TAF in 2004 the clinical data showed similar safety profiles between the two compounds. Plaintiffs counter that they are challenging conduct, not product design: Gilead, they say, unreasonably withheld a drug it had already developed and knew to be safer in order to maximize revenue from an older product, and Section 1714’s general duty of care does not disappear simply because the product is a prescription drug.15California Supreme Court. Plaintiffs JCCP 5043 Answer Brief Merits
Oral argument took place on May 6, 2026. The justices pressed both sides on how a jury could assess the “reasonableness” of complex drug-development choices without a workable standard, and several suggested the question might be one for the legislature.16King & Spalding. Duty To Innovate California Supreme Court Questions Novel Product Liability Theory
What Comes Next
The court typically issues opinions within 90 days of oral argument, so a decision is expected by August 2026.16King & Spalding. Duty To Innovate California Supreme Court Questions Novel Product Liability Theory
If the court sides with Gilead, the legal theory underlying tens of thousands of pending state claims could be gutted. If the court affirms the appellate ruling, the JCCP cases return to trial court cleared to move forward, and the decision would set a precedent that could reach well beyond HIV drugs into other pharmaceutical injury claims.